DOCSLIB.ORG

Thesis 25.04.13

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thesis 25.04.13 Extemporaneously Compounded Oral Medicines in European Hospital Pharmacies Thesis submitted for the degree of Doctor of Philosophy Maria João Reis de Carvalho UCL School of Pharmacy December 2012 Extemporaneously Compounded Oral Medicines in European Hospital Pharmacies This thesis describes research conducted in the UCL School of Pharmacy between October 2006 and September 2010, under the supervision of Professor Kevin Taylor and Dr Catherine Tuleu. I certify that the research described is original and that any parts of the work that have been conducted by collaboration are clearly indicated. I also certify that I have written all the text herein and have clearly indicated by suitable citation any part of this dissertation that has already appeared in publication. ____________________________ _____________ Signature Date 2 To my grandparents Aos meus avós Maria Benedita e Humberto 3 Abstract Pharmaceutical compounding corresponds to the preparation of customised medicines in order to meet the specific needs of patients, which cannot be met by the proprietary medicines provided by the pharmaceutical industry. Historically, pharmaceutical compounding dates back to the very origins of pharmacy and, ever since, it has been an integral part of pharmacy practice. Nevertheless, little is known regarding current compounding practices in Europe and, therefore, the aim of this project was to identify and characterise the oral compounded medicines most frequently dispensed in European hospital pharmacies. The research method adopted was a large-scale, international (European) survey and the research instrument was a self-completion (country-specific) questionnaire. A total of 11 European countries were included in the research: Portugal, UK, Switzerland, Poland, Netherlands, Denmark, Slovenia, Finland, Spain, France and Germany. For most countries, a purposive sample of hospitals was contacted and invited to contribute data regarding the oral compounded medicines most frequently dispensed in their pharmacies. The pilot-study was launched in Portugal but fieldwork was undertaken in most countries. Information regarding legislation, professional organisations and information sources relevant to pharmaceutical compounding was also collected. The oral compounded medicines most frequently dispensed in hospital pharmacy varied considerably throughout Europe, from traditional cachets in Poland to complex tablets in the Netherlands and Denmark. A wide range of active substances, including NTI drugs, and dosage strengths were dispensed. Compounded medicines were prepared individually and also in batches of variable sizes. There is little consistency of compounding practices in Europe and there is a need for common legislation, professional organisations and information sources. This project corresponds to the largest and most complex research in pharmaceutical compounding across Europe and aims to contribute to the harmonisation of quality and safety of compounded medicines in Europe. Abstract | 4 Acknowledgements To my supervisors Kevin Taylor and Catherine Tuleu, for the extraordinary support, guidance and commitment to this thesis. Thank you for the expert discussions and academic skills, invaluable to my professional career. To my parents and brother, for the unconditional love and support. Thank you for the inspiration and encouragement to achieve everything in life. To Diego Romero, for the endless dedication, patience and understanding. Thank you for always being there. To Ashveena Tirvassen and Andrea Wolf, for the greatest friendships and wonderful memories in London. To João Montalvão, for the exceptional academic foundations and decisive emotional support. To Carlos Maurício Barbosa, for the continuous guidance and remarkable contributions to this thesis. To Loyd Allen, for the inspiration and encouragement towards my career on pharmaceutical compounding. To Owen Shepherd, for the friendship and opportunity to teach pharmaceutical compounding. To Catherine Baumber, for the friendship and assistance throughout this thesis. To the UCL School of Pharmacy, for the PhD research opportunity and studentship. To Farmácia Lordelo, for the support and access to compounding training in a state-of-the art laboratory. To all European pharmacists and health care professionals who contributed to this thesis. In particular, a special acknowledgement to: Jorge Brochado (Portugal); Tony Murphy, Ann Horton and Andrew Lowey (UK); Hans Stötter and Bettina Gasser (Switzerland); Małgorzata Sznitowska and Aleksandra Neubauer-Vasquez (Poland); Frits Boom and Yvonne Bouwman (Netherlands); Daniel Bar-Shalom, Trine Schnor and Line Poulsen (Denmark); Spela Godec, Tomi Laptoš and Jure Bračun (Slovenia); Anne Juppo, Hanna Tolonen and Kristine Salminen (Finland); Diego Marro, José María Herreros and Manuela Atienza (Spain); Jörg Breitkreutz (Germany). Acknowledgements | 5 Table of Contents Page Abstract ......................................................................................................... 4 Acknowledgements ....................................................................................... 5 Table of Contents ........................................................................................ 6 List of Figures ............................................................................................. 9 List of Tables ............................................................................................. 11 List of Abbreviations .................................................................................... 13 1. Introduction ........................................................................................... 16 1.1 Pharmaceutical compounding ......................................................... 16 1.2 Hospital pharmacy ........................................................................... 34 1.3 Aim and objectives ........................................................................... 38 2. Methodology ......................................................................................... 39 2.1 International survey ......................................................................... 40 2.2 Sampling methods ........................................................................... 48 2.3 Data collection ................................................................................. 54 2.4 Data processing and analysis .......................................................... 55 3. Compounding in Portugal ..................................................................... 60 3.1 Legislation ........................................................................................ 62 3.2 Professional organisations and information sources ....................... 65 3.3 Methods ........................................................................................... 68 3.4 Results and discussion .................................................................... 77 3.5 Summary ......................................................................................... 94 4. Compounding in the UK ........................................................................ 95 4.1 Legislation ........................................................................................ 98 4.2 Professional organisations and information sources ..................... 100 4.3 Methods ......................................................................................... 103 4.4 Results and discussion .................................................................. 108 4.5 Summary ....................................................................................... 122 5. Compounding in Switzerland .............................................................. 123 5.1 Legislation ...................................................................................... 125 Table of Contents | 6 5.2 Professional organisations and information sources ..................... 126 5.3 Methods ......................................................................................... 128 5.4 Results and discussion .................................................................. 131 5.5 Summary ....................................................................................... 142 6. Compounding in Poland ...................................................................... 143 6.1 Legislation ...................................................................................... 144 6.2 Professional organisations and information sources ..................... 145 6.3 Methods ......................................................................................... 146 6.4 Results and discussion .................................................................. 149 6.5 Summary ....................................................................................... 159 7. Compounding in the Netherlands ....................................................... 160 7.1 Legislation ...................................................................................... 162 7.2 Professional organisations and information sources ..................... 163 7.3 Methods ......................................................................................... 165 7.4 Results and discussion .................................................................. 170 7.5 Summary ....................................................................................... 183 8. Compounding in Denmark .................................................................
Load more

Recommended publications
  • Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
    toxins Review Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 1 2 3, 4, , Marie-Line Reynaert , Denis Dupoiron , Edouard Yeramian y, Laurent Marsollier * y and 1, , Priscille Brodin * y 1 France Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France 2 Institut de Cancérologie de l’Ouest Paul Papin, 15 rue André Boquel-49055 Angers, France 3 Unité de Microbiologie Structurale, Institut Pasteur, CNRS, Univ. Paris, F-75015 Paris, France 4 Equipe ATIP AVENIR, CRCINA, INSERM, Univ. Nantes, Univ. Angers, 4 rue Larrey, F-49933 Angers, France * Correspondence: [email protected] (L.M.); [email protected] (P.B.) These three authors contribute equally to this work. y Received: 29 June 2019; Accepted: 3 September 2019; Published: 4 September 2019 Abstract: Pain currently represents the most common symptom for which medical attention is sought by patients. The available treatments have limited effectiveness and significant side-effects. In addition, most often, the duration of analgesia is short. Today, the handling of pain remains a major challenge. One promising alternative for the discovery of novel potent analgesics is to take inspiration from Mother Nature; in this context, the detailed investigation of the intriguing analgesia implemented in Buruli ulcer, an infectious disease caused by the bacterium Mycobacterium ulcerans and characterized by painless ulcerative lesions, seems particularly promising. More precisely, in this disease, the painless skin ulcers are caused by mycolactone, a polyketide lactone exotoxin. In fact, mycolactone exerts a wide range of effects on the host, besides being responsible for analgesia, as it has been shown notably to modulate the immune response or to provoke apoptosis.
    [Show full text]
  • Revista Medica Hondurena
    Revista MEDICA HONDURENA (2* Época) ÓRGANO DEL COLEGIO MEDICO DE HONDURAS FUNDADA EN 1930 CONSEJO EDITORIAL RICARDO VILLELA VIDAL Director RIGOBERTO ARRIAGA CHINCHILLA Secretario Redactores: HENA CARDONA DE HERRERA ARMANDO PAVÓN AGUILERA CARLOS H. RIVERA MEDINA JORGE TULIO GALEAS A. Administración: "COLEGIO MEDICO DE HONDURAS" Oficina' "Colegio Médico de Honduras", Tegucigalpa, D. C. Tel. 22-5466 Apartado Postal N9 810 SE SOLICITA CANJE Imprenta LÓPEZ Y CÍA. EDITORIAL DR. RICARDO VILLELA-VIDAL Con la publicación de este número ha terminado la misión a nosotros enco- mendada, es decir, darle vida por un año al órgano oficial de publicidad del Colegio Médico de Honduras: La REVISTA MEDICA HONDURENA. Seguros de haber cumplido con nuestro deber, dejamos en manos de los nombrados para sucedemos nuestra querida Revista. Y decimos nuestra porque ya forman parte de nuestra existencia el trabajo, el recuerdo y nuestra voluntad convertida en páginas escritas que llegaron —seguramente— como mensajeras del pensamiento médico hondureño hasta nuestros colegas paisanos, y más allá de las fronteras hondureñas. Nuestro trabajo sólo fue posible siguiendo la ruta trazada por quienes, en años anteriores, dieron vida e importancia (con esfuerzo y sacrificio) a tas1 páginas de la REVISTA MEDICA HONDURENA. Es indudable que en cada año por venir, con mejor estilo, con más trabajo y mayor buena voluntad, la Revista Médica Hondureña irá adquiriendo belleza y más prestigio. Es que nuevos valores médicos llegan año con año para surtir sus páginas con el producto de sus estudios e investigaciones en el campo interminable de las ciencias médicas. Las páginas que llevan y traen los nuevos conocimientos médicos deben ser las primeras que se abran cada día ante los ojos de los médicos de aquí y de allá, porque no podemos avanzar sin estudiar lo nuevo, sin recordar lo histórico y sin esperar cada día la llegada de los adelantos científicos.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Clinical Pharmacokinetics 42: 223-282, No. 3, 2003
    Clin Pharmacokinet 2003; 42 (3): 223-282 DRUG INTERACTIONS 0312-5963/03/0003-0223/$30.00/0 © Adis International Limited. All rights reserved. Drug Interactions Between Antiretroviral Drugs and Comedicated Agents Monique M.R. de Maat,1 G. Corine Ekhart,1 Alwin D.R. Huitema,1 Cornelis H.W. Koks,1 Jan W. Mulder2 and Jos H. Beijnen1,3 1 Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands 2 Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands 3 Faculty of Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands Contents Abstract . 223 1. Methods . 224 2. Pharmacokinetics of Antiretroviral Drugs . 225 2.1 Nucleoside Reverse Transcriptase Inhibitors . 225 2.2 Non-Nucleoside Reverse Transcriptase Inhibitors . 225 2.3 Protease Inhibitors . 225 3. Mechanisms of Drug Interaction . 225 3.1 Pharmacokinetic Interactions . 227 3.1.1 Drug Absorption . 227 3.1.2 Metabolism and P-Glycoprotein . 227 3.1.3 Protein Binding . 273 3.1.4 Excretion . 274 3.2 Pharmacodynamic Interactions . 274 3.2.1 Efficacy . 274 3.2.2 Toxicity . 274 4. Practical Issues for Use of Interactions Table . 274 5. Conclusions . 275 Abstract HIV-infected individuals usually receive a wide variety of drugs in addition to their antiretroviral drug regimen. Since both non-nucleoside reverse trans- criptase inhibitors and protease inhibitors are extensively metabolised by the cytochrome P450 system, there is a considerable potential for pharmacokinetic drug interactions when they are administered concomitantly with other drugs metabolised via the same pathway. In addition, protease inhibitors are substrates as well as inhibitors of the drug transporter P-glycoprotein, which also can result in pharmacokinetic drug interactions.
    [Show full text]
  • Package Leaflet: Information for the User
    ENR 2186544 ENR 2186545 PACKAGE LEAFLET: INFORMATION FOR THE USER <invented name> 100 mg capsules, hard Active substance: flupirtine maleate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. What is in this leaflet 1. What <invented name> is and what it is used for 2. What you need to know before you take <invented name> 3. How to take <invented name> 4. Possible side effects 5. How to store <invented name> 6. Contents of the pack and other information 1. What <invented name> is and what it is used for <invented name> is a medicine used to treat acute pain of mild to moderate intensity coming from various origins. 2. What you need to know before you take <invented name> Do not take <invented name> - if you are allergic to flupirtine maleate or any of the other ingredients of this medicine (listed in section 6). - if you are at risk of hepatic encephalopathy and patients with cholestasis, <invented name> should not be administered, as onset or deterioration of encephalopathy or ataxia may occur in these patients.
    [Show full text]
  • Muscle Relaxants for Pain Management in Rheumatoid Arthritis (Review)
    Muscle relaxants for pain management in rheumatoid arthritis (Review) Richards BL, Whittle SL, Buchbinder R This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 1 http://www.thecochranelibrary.com Muscle relaxants for pain management in rheumatoid arthritis (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 10 Figure1. ..................................... 11 Figure2. ..................................... 13 Figure3. ..................................... 15 Figure4. ..................................... 15 Figure5. ..................................... 16 Figure6. ..................................... 17 Figure7. ..................................... 17 Figure8. ..................................... 18 DISCUSSION ..................................... 20 AUTHORS’CONCLUSIONS . 21 ACKNOWLEDGEMENTS . 22 REFERENCES ..................................... 22 CHARACTERISTICSOFSTUDIES . 24 DATAANDANALYSES. 35 Analysis 1.1. Comparison 1 Muscle relaxant versus control, Outcome 1 Pain 24hrs. 37 Analysis 1.2. Comparison 1 Muscle relaxant
    [Show full text]
  • 022345Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022345Orig1s000 OTHER REVIEW(S) SEALD LABELING: PI SIGN-OFF REVIEW APPLICATION NUMBER NDA 022345 APPLICANT Valeant Pharm N.A. PRODUCT NAME Potiga (ezogabine) SUBMISSION DATE 15 April 2011 PDUFA DATE 15 June 2011 SEALD SIGN-OFF DATE 10 June 2011 OND ASSOCIATE DIRECTOR Laurie Burke FOR STUDY ENDPOINTS AND LABELING This memo confirms that no critical prescribing information (PI) deficiencies were noted in the SEALD Labeling Review filed 8 June 2011 and no critical deficiencies have been found in the final agreed-upon PI reviewed today. SEALD has no objection to PI approval at this time. Reference ID: 2959126 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- LAURIE B BURKE 06/10/2011 Reference ID: 2959126 NDA 22345 Potiga Potiga PMR/PMC Development Template: PREA Efficacy/Safety Study for Ezogabine PMR # 1 This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package. PMR/PMC Description: Prospective, randomized, placebo-control, double-blinded efficacy/ safety trial of Potiga (ezogabine) in children >12 years old. PMR/PMC Schedule Milestones: Final protocol Submission Date: 11/2012 Study/Clinical trial Completion Date: 01/2018 Final Report Submission Date: 05/2018 Other: MM/DD/YYYY 1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe. Unmet need Life-threatening condition Long-term data needed Only feasible to conduct post-approval Prior clinical experience indicates safety Small subpopulation affected Theoretical concern Other This is part of a PREA requirement.
    [Show full text]
  • Activation of Axonal Kv7 Channels In
    Fleckenstein et al. Journal of Translational Medicine 2013, 11:34 http://www.translational-medicine.com/content/11/1/34 RESEARCH Open Access Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial Johannes Fleckenstein1*, Ruth Sittl1,2, Beate Averbeck2, Philip M Lang1, Dominik Irnich1 and Richard W Carr2,3 Abstract Background: Flupirtine is an analgesic with muscle-relaxing properties that activates Kv7 potassium channels. Kv7 channels are expressed along myelinated and unmyelinated peripheral axons where their activation is expected to reduce axonal excitability and potentially contribute to flupirtine’s clinical profile. Trial design: To investigate the electrical excitability of peripheral myelinated axons following orally administered flupirtine, in-vitro experiments on isolated peripheral nerve segments were combined with a randomised, double-blind, placebo-controlled, phase I clinical trial (RCT). Methods: Threshold tracking was used to assess the electrical excitability of myelinated axons in isolated segments of human sural nerve in vitro and motoneurones to abductor pollicis brevis (APB) in situ in healthy subjects. In addition, the effect of flupirtine on ectopic action potential generation in myelinated axons was examined using ischemia of the lower arm. Results: Flupirtine (3-30 μM) shortened the relative refractory period and increased post-conditioned superexcitability in human myelinated axons in vitro. Similarly, in healthy subjects the relative refractory period of motoneurones to APB was reduced 2 hours after oral flupirtine but not following placebo. Whether this effect was due to a direct action of flupirtine on peripheral axons or temperature could not be resolved.
    [Show full text]
  • Maxillary Nerve Block – a Useful Supplementary Technique in the Management of Trigeminal Neuralgia- a Case Report
    Case Report Maxillary nerve block – a useful supplementary technique in the management of trigeminal neuralgia- a case report Janani N*, Parthasarathy S Department of Anesthesiology, Mahatma Gandhi Medical ABSTRACT College and Research Institute, Sri Balaji Vidyapeeth, A 62 year old male patient presented with complaints of left sided facial pain for 1 year. (Deemed to be University), Patient was diagnosed to be a case of trigeminal neuralgia predominantly affecting Pillaiyarkuppam, the maxillary region after a thorough clinical examination by different specialties and Puducherry-607402, investigations. Analgesics, antidepressants decreased pain but were unsatisfactory. Increased doses caused more sedation and decreased quality of life. An extra oral single shot maxillary nerve block was given and single drug therapy was continued. Satisfactory analgesia was noticed after a month. This case reports traditional extra oral maxillary nerve block as an adjuvant option for long term pain relief for trigeminal neuralgia. Keywords: Neuralgia, trigeminal, nerve block, maxillary For Correspondence INTRODUCTION episodic pain over the left side of face *Dr. Janani Nandakumar, for past 1 year. Pain was associated with Email: [email protected] Trigeminal neuralgia as defined by eating, swallowing, clenching his teeth, Date of International Association for Study of washing face and aggravated with mild Submisssion: 13-01-2019 Pain (IASP) is sudden, usually unilateral, cutaneous or sensory stimuli. He had Acceptance: 04-02-2019 severe brief stabbing recurrent pain severe , intermittent , neuropathic pain in the distribution of one or more with VAS of 9/10. He was on tablet branches of the fifth cranial nerve. With topiramate 50 mg BD, tablet flupirtine an incidence of 0.03 to 0.3%, women 100 mg BD for past 2 months and then are more affected than men (2:1).
    [Show full text]
  • Neonatal Seizures
    Neonatal Seizures Treatment Controversies and Options A clinical perspective K. S. Krishnamoorthy MD Pediatric Neurology Division Mass General Hospital Neonatal Seizures Most common for a consult in the newborn ICU It can be dramatic and anxiety provoking Incidence varies: 1- 3.5/1000 live births in term infants Higher reported in premies Families concerned about consequences and later epilepsy Neonatal Seizures 1970- 2017 Milestones § HIE was the most common etiology and Phenobarbital was the first line drug used § Physiology: GABA is inhibitory(1970’s) GABA is excitatory( 2000’s) § Brain injury- most studies are still based on animal models § Extent of brain injury in human neonates is now defined by MRI/MRS § Standard snap shot EEG is replaced by use LTM-EEG technology in tertiary centers § Emphasis on aggressive treatment of electographic seizures § Etiology of seizures better identified by 4 major tools: MRI/MRS Neurometabolic studies Epilepsy genetic panels Placental Pathology Neonatal Seizures 1970- 2017 Major Milestones 2017 HIE ( perinatal encephalopathy)still remains the most common etiology *Phenobarbital slightly declined in use still remains the first line drug (96%) *Use of phenytoin has significantly declined *Use of Levetiracetam ( Keppra ) has increased ten-fold *Ahmad K J Perinatol 2016; El-Dib Mohamed Semin Fet & Neonat Med 2017 Neonatal Seizures What about controversies ……....? Neonatal Seizures Controversies Controversies concerning Neonatal Seizures. Scher,MS and Painter MJ/ Pediatr Clinics of North America 1989; 36 : 281 Controversies in the diagnosis and management of Neonatal Seizures . Low PS.J Singapore Paediatr Soc 1991; 33: 6-10 Controversies in treatment of Neonatal Seizures. Hahn JS. Pediatr Neurol 1993; 9: 330-1 Controversies in treatment of Neonatal Seizures Young RSK Pediatr Neurol 1993; 9: 331-2 Neonatal seizures : Diagnostic and Therapeutic Controversies Legido A.
    [Show full text]
  • (SNEPCO) Flupirtine in Treatment-Resistant Epilepsy
    Mental Health and Addiction Research Research Article ISSN: 2398-5380 Selective neuronal potassium channel opener (SNEPCO) flupirtine in treatment-resistant epilepsy comorbid depression in adults Nadir A Aliyev1*, Zafar N Aliyev2 and Sona E Aliyeva3 1Azerbaijan State Advanced Training Institute for Doctors named by A. Aliyev department of psychiatry and drug addiction, Baku, Azerbaijan Republic 2Azerbaijan Medical State University, Department of Psychiatry Baku City, Azerbaijan Republic 3Azerbaijan Medical State University, Department of Neurology Baku City, Azerbaijan Republic Abstract Objective: Despite the presence of more than 20 antiepileptic drugs, in 30% of patients with epilepsy the control of seizures is not achieved. The study was to investigate the efficacy of flupirtine, anticonvulsant drug with a new mechanism of action, in the form of activation of potassium channels. Methods: A total of 100 patients with pharmacoresistent epilepsy in adults and non-psychotic depression, associated with this disease, were included in the study. The dynamics of the frequency of seizures and the intensity of depressive disorders was studied by using the Hamilton Scale. Results: In 60 % of cases treated with flupirtine therapeutic remission was achieved with cessation of seizures, in the rest observations marked reduction of seizures was noticed. At the same time a decrease of the severity of depression was registered. Significance: Flupirtine is an effective drug in the treatment of pharmacoresistent epilepsy in adults with non-psychotic depressive disorder. Introduction The purpose of this work was to study the possibility of using flupirtine (cadadolone) - SNEPCO (Selective Neuronal Potassium Epidemiological studies show that epilepsy is one of the most Channel Opener) - in the therapy of resistant epilepsy and a common neurological diseases with certain mental disorders.
    [Show full text]
  • A Case of Green Urine Caused by Flupirtine Intoxication
    Open Access Case Report DOI: 10.7759/cureus.12333 Hulk-Like Urine: A Case of Green Urine Caused by Flupirtine Intoxication Maria Vilela 1 , Diana Fernandes 2 , Tatiana Salazar Sr. 2 , Augusto Duarte 1 1. Internal Medicine, Centro Hospitalar do Médio Ave, Vila Nova de Famalicão, PRT 2. Internal Medicine, Centro Hospitalar Do Médio Ave, Vila Nova de Famalicão, PRT Corresponding author: Maria Vilela, [email protected] Abstract Acute intoxications are common causes of admission to the Emergency Department (ED). Flupirtine is a non-opioid analgesic, originally used for acute and chronic pain. Because of several reports of severe liver toxicity, its use was limited to acute pain in 2013 by the European Medicines Agency. Although withdrawn from the European market in March 2018, there are still flupirtine tablets in many households, and most people are unaware of the hazards they might be facing. A 58-year-old man was admitted to the ED after a suicide attempt with 1 g of flupirtine. He was lethargic and confused but presented no focal neurological deficits or other symptoms, and the rest of his clinical examination was unremarkable. His cerebral CAT and blood chemistry showed no alterations. The only remarkable feature was that he had green urine. After a careful literature search, a similar case was found caused by flupirtine intoxication. After 24 hours of vigilance in the ED, he improved his neurological status and his urine lost part of its greenish color. He was then transferred to the Psychiatric Department, where he presented a complete remission of the clinical alterations. A follow-up check-up showed no permanent deficits.
    [Show full text]